Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender Sells 10,681 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 10,681 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $149,534.00. Following the completion of the sale, the chief executive officer now owns 98,932 shares in the company, valued at $1,385,048. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Day One Biopharmaceuticals Stock Up 1.2 %

Shares of DAWN opened at $14.09 on Tuesday. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $18.07. The stock has a market capitalization of $1.23 billion, a P/E ratio of -5.61 and a beta of -1.51. The company has a 50 day moving average of $14.07 and a 200-day moving average of $14.79.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.70. The business had revenue of $8.19 million during the quarter, compared to the consensus estimate of $0.90 million. On average, sell-side analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently modified their holdings of DAWN. Quest Partners LLC acquired a new position in Day One Biopharmaceuticals during the fourth quarter valued at approximately $29,000. Quintet Private Bank Europe S.A. raised its stake in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Day One Biopharmaceuticals in the 2nd quarter valued at approximately $113,000. Point72 DIFC Ltd bought a new position in shares of Day One Biopharmaceuticals in the second quarter valued at $124,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Day One Biopharmaceuticals during the fourth quarter worth $156,000. Institutional investors own 87.95% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on DAWN. JPMorgan Chase & Co. reduced their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st. Piper Sandler reissued an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, July 30th. Finally, Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.